Arcutis Biotherapeutics, Inc. (ARQT)
| Market Cap | 2.66B +61.9% |
| Revenue (ttm) | 415.62M +95.3% |
| Net Income | -2.38M |
| EPS | -0.02 |
| Shares Out | 125.08M |
| PE Ratio | n/a |
| Forward PE | 70.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,209,409 |
| Open | 21.85 |
| Previous Close | 21.95 |
| Day's Range | 21.03 - 22.19 |
| 52-Week Range | 12.72 - 31.77 |
| Beta | 1.52 |
| Analysts | Buy |
| Price Target | 34.63 (+63.12%) |
| Earnings Date | May 6, 2026 |
About ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Bio... [Read more]
Financial Performance
In 2025, Arcutis Biotherapeutics's revenue was $376.07 million, an increase of 91.34% compared to the previous year's $196.54 million. Losses were -$16.14 million, -88.47% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ARQT stock is "Buy." The 12-month stock price target is $34.63, which is an increase of 63.12% from the latest price.
News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Arcutis Biotherapeutics Transcript: AGM 2026
The meeting confirmed quorum and proceeded with the election of three directors, ratification of the auditor, and approval of executive compensation. All proposals passed, with final results to be filed with the SEC.
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populations This is the second published manuscript from the...
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Arcutis today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference, taking place June 8-10, 2026, in Miami.
Arcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Arcutis Biotherapeutics (ARQT) to $34 from $35 and keeps an Overweight rating on the shares.
Arcutis Biotherapeutics reports Q1 EPS (9c), consensus (6c)
Reports Q1 revenue $105.4M, consensus $103.66M. “Strong product revenue in the first quarter was driven by continued robust demand for ZORYVE, which remains the leading prescribed branded topical acro...
Arcutis Biotherapeutics backs FY26 revenue view $480M-$495M, consensus $498.07M
The company said, “The Company continues to anticipate net product revenue of between $480 million and $495 million for the full year 2026.”
Arcutis Biotherapeutics Earnings Call Transcript: Q1 2026
Net product revenues grew 65% year-over-year to $105.4 million, with ZORYVE gaining market share and maintaining strong prescription trends despite Q1 seasonality and weather impacts. Full-year revenue guidance remains $480–$495 million, with continued investment in sales force and pipeline expected to drive future growth.
Arcutis Biotherapeutics Earnings release: Q1 2026
Arcutis Biotherapeutics released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Arcutis Biotherapeutics Quarterly report: Q1 2026
Arcutis Biotherapeutics has published its Q1 2026 quarterly earnings report on May 6, 2026.
Arcutis Biotherapeutics Slides: Q1 2026
Arcutis Biotherapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
Q1 2026 net product revenue for ZORYVE® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025 Continued strong demand for ZORYVE despite typical ...
Arcutis Biotherapeutics submits Zoryve supplemental new drug application
Arcutis Biotherapeutics (ARQT) announced the submission of a supplemental new drug application to the FDA seeking to expand the indication for Zoryve cream 0.05% to include the topical treatment of…
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis Once-daily ZORYVE cream was well to...
Arcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitor...
Arcutis Biotherapeutics Proxy statement: Proxy filing
Arcutis Biotherapeutics filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Arcutis Biotherapeutics Proxy statement: Proxy filing
Arcutis Biotherapeutics filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Arcutis Biotherapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
ZORYVE's strong Q4 performance and expanding indications have driven a significant increase in 2026 revenue guidance. Strategic investments in sales force and payer access, along with a robust pipeline and digital marketing, position the brand for continued growth and market leadership.
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
Arcutis today announced that Arcutis management will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16, 2026.
Arcutis Biotherapeutics Slides: Corporate presentation
Arcutis Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 31, 2026.
Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream
Arcutis Biotherapeutics (ARQT) announced new data from the Integument-Infant Phase 2 trial demonstrating that Zoryve cream 0.05% reduced signs and symptoms of atopic dermatitis, the most common form o...
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program ZORYVE cream improved signs and symptoms ...
Arcutis Biotherapeutics to present clinical data on ZORYVE at AAD Meeting
Arcutis Biotherapeutics (ARQT) will present new data from its clinical development program and marketed ZORYVE portfolio during the 2026 American Academy of Dermatology Annual Meeting taking place Mar...
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful in...